Baird raised the firm’s price target on Agenus (AGEN) to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where the cmpoany is evaluating multiple proposals which are expected to bring in capital.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Agenus’s Regulatory and Clinical Developments Prompt Neutral Stance Amid Uncertain FDA Pathway
- Agenus Inc. Reports Q1 2025 Progress and Financials
- Agenus Inc. Earnings Call: Optimism Amid Challenges
- Agenus files to sell 165,000 shares of common stock for holders
- Agenus Hold Rating: Uncertainty Amid Funding and Regulatory Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue